ALVR vs. CVM, CRIS, PASG, PLX, ATHA, JATT, CGTX, OTLK, GRTS, and DTIL
Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include CEL-SCI (CVM), Curis (CRIS), Passage Bio (PASG), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), JATT Acquisition (JATT), Cognition Therapeutics (CGTX), Outlook Therapeutics (OTLK), Gritstone bio (GRTS), and Precision BioSciences (DTIL). These companies are all part of the "biological products, except diagnostic" industry.
AlloVir (NASDAQ:ALVR) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
AlloVir has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
CEL-SCI is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
AlloVir currently has a consensus target price of $18.50, indicating a potential upside of 2,366.67%. Given AlloVir's higher probable upside, analysts clearly believe AlloVir is more favorable than CEL-SCI.
In the previous week, CEL-SCI had 4 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for CEL-SCI and 4 mentions for AlloVir. CEL-SCI's average media sentiment score of 0.90 beat AlloVir's score of -0.04 indicating that CEL-SCI is being referred to more favorably in the news media.
AlloVir received 27 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 57.45% of users gave AlloVir an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
66.1% of AlloVir shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 33.9% of AlloVir shares are held by insiders. Comparatively, 14.1% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
AlloVir's return on equity of -89.47% beat CEL-SCI's return on equity.
Summary
AlloVir beats CEL-SCI on 9 of the 14 factors compared between the two stocks.
Get AlloVir News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
